Regeneron Pharmaceuticals Inc. (NASDAQ:REGN): A Fundamentally Weighted Stock for Long-Term Investors
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has a beta of 0.17, a 12-month trailing P/E ratio of 14.81, and a growth ratio of 3.70. The stock’s Relative